GlassScriptPhysician profile
Loren S Guzman
NPI 1538521042
$1,011.26
in general payments reported to CMS, 2019-2025
10 companies · $55.69 in 2025
The $55.69 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $386 · 2021: $55.12 · 2022: $114 · 2023: $287 · 2024: $114 · 2025: $55.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $456.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $376.21 | 2020-2024 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $154.98 | 2022-2025 | |
| Spr Therapeutics, INC | $95.22 | 2020-2023 | Sprint Pns System |
| Stimwave Technologies Incorporated | $94.32 | 2020 | |
| Nevro Corp. | $89.35 | 2020 | |
| Allergan, INC. | $74.58 | 2021-2022 | |
| Medtronic, INC. | $35.67 | 2024 | Intellis Adaptivestim |
| Relievant Medsystems, INC. | $33.43 | 2023 | Intracept |
| Globus Medical, INC. | $30.76 | 2025 | Vyrsa V1 |
| Averitas Pharma INC. | $26.74 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loren Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.